Exelixis, Inc.

Location not on file

OncologyFiled/ApprovedListed · EXEL

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Filed/Approved trial registered: PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke

6d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE4 registered
Sep 1, 2026
Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque · NOT_YET_RECRUITING · sponsor: Peking Union Medical College Hospital · PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
ClinicalTrials.gov · NCT07466251 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 25, 2026
Extranodal NK/T-cell Lymphoma · NOT_YET_RECRUITING · sponsor: WEI XU · Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
ClinicalTrials.gov · NCT07385989 (opens the source filing in a new tab)
Trial
PHASE4 registered
Nov 7, 2025
Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque · RECRUITING · sponsor: Peking Union Medical College Hospital · PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
ClinicalTrials.gov · NCT06902740 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 1, 2025
Large B-cell Lymphoma, TP53 · RECRUITING · sponsor: The First Affiliated Hospital with Nanjing Medical University · The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
ClinicalTrials.gov · NCT07240194 (opens the source filing in a new tab)
Trial
Study registered
Aug 1, 2025
Sacral Tumors · NOT_YET_RECRUITING · sponsor: Shanghai Changzheng Hospital · Observational Study of Sacral Nerve Function After Sacral Tumor Resection
ClinicalTrials.gov · NCT07105644 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 1, 2025
NK-T-Cell Lymphoma, Extranodal · NOT_YET_RECRUITING · sponsor: The First Affiliated Hospital with Nanjing Medical University · A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
ClinicalTrials.gov · NCT06953739 (opens the source filing in a new tab)
Patent
Patent granted
Jan 14, 2025
assignee: Exelixis, Inc. · Compounds for the Treatment of Kinase-Dependent Disorders
USPTO · US 12195475 (opens the source filing in a new tab)
Trial
Study registered
Feb 1, 2024
Patella Fracture · RECRUITING · sponsor: Fuzhou University Affiliated Provincial Hospital · High-Strength Suture vs. Traditional Tension Band for Patellar Fractures
ClinicalTrials.gov · NCT07248982 (opens the source filing in a new tab)
Patent
Patent assigned
Oct 9, 2023
assignee: EXELIXIS, INC. · Compounds for the Treatment of Kinase-Dependent Disorders
USPTO · US 12195475 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the patent record at 0.70name similarity 100% · shared principal investigator / founder
new_entity links the patent record at 0.50name similarity 100%

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Filed/Approved trial registered: PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
6d agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
5mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: High-Strength Suture vs. Traditional Tension Band for Patellar Fractures
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: High-Strength Suture vs. Traditional Tension Band for Patellar Fractures
7mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
8mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Observational Study of Sacral Nerve Function After Sacral Tumor Resection
11mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
May 2025Trial registeredSource (opens the source filing in a new tab)
Patent granted · Compounds for the Treatment of Kinase-Dependent Disorders
Jan 2025Patent grantedSource (opens the source filing in a new tab)
Patent assigned · Compounds for the Treatment of Kinase-Dependent Disorders
Oct 2023Patent assignedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE4 registered

PHASE2 registered

PHASE4 registered

PHASE2 registered

Study registered

PHASE3 registered

Patent granted

Study registered

Patent assigned